According to AI News, according to CNBC, Lilly has applied to the United States for approval of its weight loss drug Zepbound for the treatment of the most common sleep related respiratory disorders, and regulatory agencies are expected to make a decision as early as the end of this year. The company released additional data from two later trials, showing that Zepbound helped alleviate obstructive sleep apnea in nearly half of patients.